Pfizer halts testing of twice-daily obesity drug, citing side effects
Pfizer said Friday it is halting the testing of a twice-daily obesity drug, citing side effects.
The company said in a press release it will now focus its future efforts for the drug, danuglipron, on a “once-daily formulation.” It…